ARWR

STRUCTURAL READINESS As of the close on 2026-06-13, ARWR presents a confirmed coil setup, indicating a breakout has fired. The conservative entry level for this structure is $86.55. The current price is $85.74, representing an extension of -0.9% relative to the conservative entry. The setup is currently trading slightly below the defined entry threshold, suggesting a potential retest or consolidation phase immediately following the breakout signal. The ATR at the time of the breakout was 4.7% (High bucket), and the current ATR is 4.6% (High bucket). This volatility profile sits within the historical "sweet spot" (4–6%) for structural quality, implying sufficient price movement to support a trend while maintaining manageable risk parameters for position sizing.

THE THESIS LAYER ARWR is a direct beneficiary of the Biotech & GLP-1 → Platforms, Tools & CRO/CDMO secular theme. The company's role is that of a platform provider and direct developer of RNA interference (RNAi) therapeutics, positioning it as a critical tool in the cardiometabolic and rare disease space. The thesis is reinforced by the company's strategic partnerships with major pharmaceutical entities (Amgen, Takeda, Novartis, Sarepta), which validates its platform's utility as a "tool" for larger pharma players. The directness of the exposure is high, as the company is not merely a service provider but holds the intellectual property and commercial rights to key assets like REDEMPLO, while simultaneously leveraging its platform to generate significant milestone revenue from partners.

THE BUSINESS Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, utilizing a broad portfolio of RNA chemistries and delivery modes. As of the earnings transcript dated 2026-05-07, the company has successfully commercialized its first product, REDEMPLO (plozasiran), which was approved by the FDA on November 18, 2025, for the treatment of Familial Chylomicronemia Syndrome (FCS).

Key business metrics and milestones recorded as of the source dates include:

• Commercial Traction: Management reported approximately 30 new prescriptions written each week as of May 2026, with over 400 total prescriptions written since launch. Notably, more than 10% of these prescriptions are for patients switching from competitors' APOC3 inhibitors.
• Pipeline Progress: Registrational Phase III studies (SHASTA-3 and SHASTA-4) for severe hypertriglyceridemia (sHTG) are expected to yield top-line results in Q3 2026. Management expects to file a supplemental NDA (sNDA) before the end of 2026, targeting regulatory approval in the second half of 2027.
• Partnership Revenue: The company holds a licensing agreement with Madrigal Pharmaceuticals, entitling Arrowhead to a $25 million upfront payment and up to $975 million in development, regulatory, and sales milestones. Additionally, the company is eligible for up to $2.0 billion in potential milestone payments plus royalties on commercial sales from various partners.
• Recent Milestones: On November 20, 2025, the company earned a $200 million milestone payment from Sarepta Therapeutics for reaching enrollment targets in the ARO-DM1 study.
• Capital Structure: On January 7, 2026, the company issued $700.0 million in 0.00% Notes due 2032, providing significant liquidity to support its commercial expansion and clinical programs.

ARCHETYPE AND CONVICTION ARWR fits the Quality Compounder archetype. The company has transitioned from a pure clinical-stage biotech to a commercial entity with a validated product (REDEMPLO) and a robust pipeline of late-stage assets. The financial spine indicates continued losses with forward consensus EPS of -3.12 for FY1 and -3.89 for FY2, which is typical for a company in the commercialization and late-stage expansion phase, but the massive milestone potential and upfront capital raise mitigate near-term dilution risk.

The conviction is supported by:

• Thesis Strength: Direct exposure to the high-growth cardiometabolic and rare disease sectors, validated by the GLP-1 combination data (ARO-INHBE) showing enhanced weight loss and fat reduction.
• Evidence Quality: Strong, primary evidence from earnings transcripts and SEC filings confirming commercial traction, regulatory approvals, and significant milestone payments.
• Structural Quality: The ATR at breakout (4.7%) and current ATR (4.6%) indicate a healthy, active market with sufficient volatility to support a trend, avoiding the "weak" sub-threshold volatility often seen in stagnant names.
• Setup Readiness: The confirmed coil setup provides a structural foundation for price appreciation, though the current price is slightly below the conservative entry, requiring a hold or retest before full commitment.

INVALIDATION AND GAPS

• Invalidation Factors: A failure to meet the Q3 2026 top-line data expectations for SHASTA-3 and SHASTA-4, or a significant delay in the sNDA filing beyond the end of 2026, would materially weaken the thesis. Additionally, a failure of REDEMPLO to maintain prescription growth or a significant drop in prescriber satisfaction (currently reported as high) would be a negative signal.
• Strengthening Factors: Positive early data from the ARO-DIMER-PA or ARO-MAPT studies in Q3/Q4 2026, or the announcement of additional major partnership milestones, would strengthen the case.
• Evidence Gaps: While the commercial launch is confirmed, specific revenue run-rate figures for REDEMPLO beyond the prescription count are not explicitly detailed in the provided evidence. Furthermore, the exact timeline for the expansion of the commercial footprint for the higher-prevalence sHTG indication is described as "progressive" but lacks a specific date in the current evidence set.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: REDEMPLO commercial traction with 30+ weekly prescriptions and 10% switch rate; confirmed Phase III data readout expected Q3 2026; $700M capital raise and $200M Sarepta milestone secured. Key risks: Delay in sNDA filing or regulatory approval for sHTG; failure of Phase III data to meet endpoints; execution risk in scaling commercial team for sHTG. Rating boundary: The rating is a Buy rather than a Strong Buy because the current price is trading below the conservative entry level (-0.9% extension), indicating the setup is in a retest phase rather than a confirmed momentum continuation. A Strong Buy would require a confirmed close above the $86.55 entry level with volume confirmation. The rating would drop to Speculative if the Q3 data readout is delayed or if the sNDA filing is pushed beyond the end of 2026. Sizing hint: Position size should reflect the high ATR volatility and the current price proximity to the entry level; consider scaling in on a confirmed retest of the entry level. Expected path: Management expects to file the sNDA for sHTG by end of 2026, with approval targeted for late 2027. Commercial expansion for sHTG will require a larger footprint, likely driving revenue growth in the 2027-2028 timeframe. Expected horizon: 12 to 24 months for the sHTG approval and commercial ramp to fully play out. Failure mode to watch: The single most important failure mode is a negative or inconclusive top-line result from the SHASTA-3 or SHASTA-4 Phase III studies in Q3 2026, which would derail the primary growth catalyst.